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Abbreviations 
ABL1                          ABL proto-oncogene 1, non-receptor tyrosine kinase 
B2M                            Beta-2 microglobulin 
CDKN1A/P21             Cyclin-dependent kinase inhibitor 1A 
CRC                            Colorectal Cancer 
DTC                            Disseminated Tumor Cell 
FBS                             Fetal Bovine Serum 
GDP                            Guanosine diphosphate 
GIT1                           G protein-coupled receptor kinase interacting ArfGAP 1  
GRB7                          Growth factor receptor-bound protein 7 
GTP                            Guanosine triphosphate 
HCV                           Hepatitis C virus 
ITGAL                        Integrin, alpha L 
miRNA                       microRNA  
PBS                             Phosphate Buffered Saline 
PCR                            Polymearase Chain Reaction 
Pri-miRNA                 Primary microRNA 
Pre-miRNA                Preliminary microRNA 
qPCR/RT-PCR           real-time quantitative polymerase chain reaction 
RABL6/C9orf86         RAB, member RAS oncogene family-like 6 
RIMS1                        Regulating synaptic membrane exocytosis 1 
RIPA                           Radioimmunoprecipitation assay (buffer) 
RNU6-2                      U6 small nuclear 2 RNA 
RRN18S                     18S ribosomal RNA 
SNO68                        Small nucleolar RNA 68 
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1 INTRODUCTION 
Colorectal Cancer (CRC) is the third most frequently diagnosed cancer and fourth leading 
cause of cancer death in males worldwide, and remains the second and third in females, 
respectively (Torre et al., 2015). The incidence and mortality have varied gradually over past 
decades. Some areas with historically low incidences like Western Asia and Eastern Europe 
are witnessing an increase, while the trend is declining in the United States, probably due to 
the increased use of screening (Siegel et al., 2017; Torre et al., 2015). However, there are still 
approximately 1.4 million cases and more than 0.6 million deaths every year (Jemal et al., 
2011; Torre et al., 2015).  Metastasis is the leading cause of CRC deaths and the liver is the 
most common metastasis site. Nearly 50% - 60% CRC patients are diagnosed with 
synchronous metastases, 80% of which have liver metastases (Stangl, Altendorf-Hofmann, 
Charnley, & Scheele, 1994; Yoo, Lopez-Soler, Longo, & Cha, 2006). Surgery is still 
advocated even in the absence of liver metastasis and 5-year survival rates are lower in 
patients with liver metastasis not undergoing surgery (Van Cutsem et al., 2006). Besides 
surgery, for disseminated CRC, there are systemic therapies including various drugs, either in 
combination or as single agents. Although these methods have prolonged patients’ survival, 
outcomes are still far from desirable (Bosset et al., 2014). Tumor heterogeneity occurring 
throughout the progression and dissemination processes account for the low response rates of 
single drugs (Wolpin & Mayer, 2008). The process is made more complex by the various 
molecular regulators that are involved. 
The Metastasis cascade 
Metastasis is multistage process with an orderly sequence of basic steps comprising local 
invasion, intravasation, survival in the circulation, extravasation, formation of 
micrometastasis and colonization (Poste & Fidler, 1980; Steeg, 2006). These steps are often 
broken down into two main phases; that of the physical dissemination of tumor cells from the 
primary tumor to distant tissues, and that of the adaptation of these cells to foreign 
microenvironments resulting in successful colonization (McGowan, Kirstein, & Chambers, 
2009; Peinado, Lavotshkin, & Lyden, 2011; Talmadge & Fidler, 2010). Considerably, 
evidence has recently surfaced indicating that cells can disseminate remarkably early, 
dispersing from seemingly noninvasive premalignant lesions in both mice and humans 
(Coghlin & Murray, 2010; Klein, 2009). Contrary to earlier assumptions, oncogenic 
transformation on its own is insufficient to confer metastatic competence, as demonstrated by 
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the observation of patients with disseminated tumor cells (DTCs) that do not develop overt 
clinical metastasis and that of many oncogene driven mouse models of cancer that failed to 
establish distant metastasis (Klein, 2003; Minna, Kurie, & Jacks, 2003). Furthermore, failure 
or insufficiency at any of the steps is a potential rate limiting step and could stop the entire 
cascade (Nguyen, Bos, & Massague, 2009). 
Metastasis begins with a loss of cell-cell adhesion, which is the prerequisite for dissociation of 
tumor cells from the primary tumor. Thereafter, local invasion and migration into the 
surrounding tissue occurs via the proteolytic degradation of the extracellular matrix. After 
intravasation into the peripheral blood circulation, the cells must first escape the immune 
defenses, adhere to a vessel wall somewhere in the body, and finally invade into the tissue and 
establish a secondary tumor (Coghlin & Murray, 2010; Jiang, Puntis, & Hallett, 1994). 
Induction of neoangiogenesis ensures the growth of the metastasis and the sufficient supply of 
nutrients (Carmeliet & Jain, 2011). 
The proteolytic degradation of extracellular matrix structures and basement membranes 
during metastasis is carried out by various tumor-associated protease systems, such as serine, 
aspartate, cysteine and threonine metalloproteinases (Blasi & Carmeliet, 2002; Geho, Bandle, 
Clair, & Liotta, 2005; Kessenbrock, Plaks, & Werb, 2010). These enzymes do not differ from 
those that control physiological processes such as wound healing, inflammation, 
embryogenesis or angiogenesis (Dvorak, 1986; Kessenbrock et al., 2010). Rather, the 
overexpression of these enzymes is the defining characteristic of the invasive phenotype of 
malignant cells. 
Metastatic colonization 
A prominent feature of metastasis is the ability of different tumor types to colonize the same 
or different organ sites, but interestingly, different tumor types tend to metastasize to specific 
organ sites with certain tumor types showing a limited range of target tissues. In the initial 
phases, most disseminated tumor cells are likely to be poorly adapted to the 
microenvironment of the tissue in which they have settled. An acclimatization to this new 
environment needs to occur requiring colonization programs that are often tumor specific and 
dependent on the nature of the ‘would be’ colonized tissue microenvironment. Organ specific 
colonization functions in the case of bone metastasis are relatively well established, and for 
example, the ability of breast cancer cells to form typical osteolytic metastasis requires the 
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production of osteoclast activating factors PTHRP, IL-11, IL-6, TNFα and GM-CSF. GM-CSF 
directly promotes osteoclastogenesis while the rest of the cytokines induce osteoclast 
formation via the induction of RANKL, a nuclear factor-κβ ligand. The expression of these 
secreted factors would be unlikely to provide a selective advantage in another metastatic site 
or in the primary tumor but are essential to the development of osteolytic lesions. The 
mediators of colonization in other organ microenvironments such as the brain and liver 
remain unknown (Nguyen et al., 2009). 
The liver is a common metastasis site for several solid tumors, especially that of the 
gastrointestinal tract. In addition, the liver is also colonized by hematogenous tumors such as 
myelomas and leukemias. Its unique biology and anatomical location renders the liver 
particularly receptive to circulating disseminated tumor cells. The two sources of its unique 
dual blood supply (80 percent deoxygenated blood via the portal vein and 20 percent oxygen-
rich blood via the hepatic artery) come together at the point of entry into the sinusoids, and 
the mixed blood supplies the liver parenchymal cells before draining via the centrilobular 
veins. Circulating tumor cells can enter the liver through both vascular entry ports. 
The normal liver actually displays inherent architectural and functional features which favor 
metastasis. These features include: (a) a liver-specific microcirculation with its unique 
sinusoidal cell population, (b) perivascular mesenchymal cells including hepatic stellate cells 
(HSCs), (c) a morphologically and metabolically heterogeneous parenchymal cell 
compartment, and (d) the hepatic regional immunity (Kruger, 2015). The distinctive 
circulatory network in the hepatic sinusoids positively contributes to the retention of 
disseminated tumor cells in the liver (Figure 1).  
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Figure 1. Inherent features of hepatic sinusoids favor metastasis (red arrows): Connection of 
sinusoids and primary tumour sites via the blood circulation and entry of TCs via the portal 
triad; perivascular portal tract fibroblasts and HSCs secrete prometastatic factors; slow blood 
flowing in microcirculation promoting attachment of TCs to HSECs; metabolically 
heterogeneous parenchymal cells and oxygen gradient; regional immune suppression by 
interactions of MDSCs with other immune cells and activated HSC (black arrows). Invasion 
of mature neutrophils (Dotted arrow). Fibr portal tract fibroblasts, Hep hepatocyte, HSC 
hepatic stellate cells, actHSC activated hepatic stellate cells, KC Kupffer cells, MDSC 
myeloid-derived suppressor cells, NK natural killer cells, NΦ neutrophil granulocytes, O2conc 
oxygen concentration, SoD space of Disse, TC tumour cell, T T lymphocyte. Figure adapted 
from (Kruger, 2015). 
Four major phases have been described in the progression of liver metastasis: (1) the 
microvascular phase, including tumor cells arrest in the sinusoidal vessels, can lead to tumor 
cell death or extravasation; (2) the extravascular, pre-angiogenic phase, during which 
avascular micrometastases appear via recruitment of host stromal cells ; (3) the angiogenic 
phase, during which endothelial cells are initiated and the tumors become vascularized via 
interactions with the microenvironment; and (4) the growth phase, which leads to the 
establishment of ‘clinical’ metastases (Van den Eynden et al., 2013).  
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MicroRNAs 
MicroRNAs (miRNAs) are small non-coding RNA molecules (18-22 nucleotides) that 
regulate gene expression (Ambros, 2004). The human genome encodes over 1000 miRNAs 
(Bentwich et al., 2005), which appear to target about 60% of the protein coding genes (Lewis, 
Burge, & Bartel, 2005). miRNA genes are usually transcribed by RNA polymerase II. The 
resulting transcript is a spliced stem-loop precursor with a 5’ cap and a poly (A) tail called 
primary miRNA (pri-miRNA) (Lee et al., 2004). A single pri-miRNA may contain one to six 
miRNA precursors. A pri-miRNA is cut by the DiGeorge Syndrome Critical Region 8 
(DGCR8), and Drosha enzymes, resulting in the formation of a precursor-miRNA (pre-
miRNA) (Conrad, Marsico, Gehre, & Orom, 2014). These are then exported out of the 
nucleus and cut by the RNase enzyme, Dicer. The final product is a mature miRNA about 
18~22 nucleotides in length (Lund & Dahlberg, 2006) (Figure 2).  
 
Figure 2. Schema of microRNA biogenesis. Figure adapted from (Winter, Jung, Keller, 
Gregory, & Diederichs, 2009). 
miRNAs function in cell regulation. A miRNA is complementary to a part of one or more 
messenger RNAs (mRNAs). Animal miRNAs are usually complementary to the 3’ UTR (X. J. 
Wang, Reyes, Chua, & Gaasterland, 2004) in a manner that is usually imperfect. miRNAs 
normally inhibit the protein translation of target mRNAs (Williams, 2008) but some miRNAs 
augment the degradation of mRNAs (Eulalio et al., 2009).  
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Most miRNAs are located within cells but some of them can be found in the extracellular 
environment like culture media and function in cell-cell signaling (Turchinovich, Weiz, & 
Burwinkel, 2012).  
MicroRNAs in Cancer and Cancer Metastasis 
Several miRNAs have been linked to cancer. MicroRNAs are deregulated in an array of solid 
cancers, as well as hematological malignancies (Lu et al., 2005). The finding that miRNAs 
have a role in cancer is reinforced by the fact that about 50 percent of miRNA genes are 
located in cancer associated genomic regions, or in fragile sites. The list of cancer-associated 
miRNAs is growing very rapidly. The deregulation of certain miRNAs has been shown to cut 
across several cancer types, for instance miR-21 is commonly up-regulated in breast, colon, 
lung, pancreas, prostate, stomach, cervical, ovarian, hepatobilliary and head and neck cancers 
as well as in B-cell lymphoma and chronic lymphocytic leukemia (Lu et al., 2005; Volinia et 
al., 2006).  
A significant number of miRNAs have been identified to be linked with CRC, such as miR-
10b (Baffa et al., 2009), miR-451 (Bitarte et al., 2011), miR-135b (Gaedcke et al., 2012), 
miR-224 (Ling et al., 2016), et al. In some of the published reports, the affected target 
proteins and implicated pathways identified were linked to the prediction and prognosis of 
metastasis in CRC. Since metastasis is the main cause of mortality, a lot of research has been 
focused on the difference between primary cancer and metastases like liver metastases. For 
instance, let-7i and miR-10b were significantly downregulated in liver metastases compared 
with primary CRC (Hur et al., 2015).  
The Allgayer group has done a considerable amount of work on miRNAs and colorectal 
cancer metastases (Asangani et al., 2008; Ceppi et al., 2010; Kumarswamy et al., 2012; 
Laudato et al., 2017; Mudduluru et al., 2011). The group identified an exclusive miRNA 
signature that is differently expressed in metastases. Three of these miRNAs were identified 
as key drivers of an EMT-regulating network acting through a number of novel targets 
including SIAH1, SETD2, ZEB2 and especially FOXN3, which suppress the transcription of 
N-cadherin. The modulation of N-cadherin impacted on the migration, invasion and 
metastasis of cancer cells (Mudduluru et al., 2015). Similarly, the group found the miRs-134 
and -370 to be potential tumor suppressor miRNAs that could suppress colorectal cancer 
tumorigenesis by regulating the EGFR signaling cascade (El-Daly, Abba, Patil, & Allgayer, 
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2016).   
miR-122 
miR-122 is highly abundant and specific to the liver and this microRNA plays a critical role in 
liver homeostasis by regulating the expression of a large number of target mRNAs and also by 
suppressing non-hepatic genes (Fu et al., 2005; Landgraf et al., 2007). It is normally known to 
be involved in the regulation of numerous transcripts encoding a variety of hepatic processes, 
like cholesterol and lipid metabolism (Esau et al., 2006), mitochondrial function (Burchard et 
al., 2010), polyploidy regulation (Hsu et al., 2016), hepatitis C virus replication (Jopling, Yi, 
Lancaster, Lemon, & Sarnow, 2005), and liver tumor suppression (Tsai et al., 2009). Hepatic 
and circulating levels of miR-122 are a prognostic marker in patients with hepatocellular 
carcinoma (Coulouarn, Factor, Andersen, Durkin, & Thorgeirsson, 2009).  
Several liver-enriched transcription factors, e.g. C/EBPα, HNF1α, HNF3β, and HNF4α 
(Coulouarn et al., 2009; Xu et al., 2010) and HNF6 (Laudadio et al., 2012) were shown to 
activate miR-122 gene expression in hepatic cell lines. Furthermore, miR-122 has been 
identified to regulate a large set of target genes. In fact, the first miR-122 target identified was 
the gene cationic amino acid transporter 1 (CAT-1) or Slc7a1 (J. Chang et al., 2004), which is 
expressed in many other adult tissue types and strongly expressed in fetal liver, yet under 
normal un-stressed circumstances, is repressed in adult hepatocytes (Krutzfeldt et al., 2005). 
As a tumor suppressor, miR-122 suppresses c-Myc transcription by targeting E2f1, a 
transcriptional activator, and Tfdp2, a co-activator. Whereas c-Myc suppresses miR-122 
expression directly by binding to its promoter region and indirectly by downregulating several 
liver enriched transcription factors (B. Wang et al., 2014). There are other oncogenes 
identified as its targets, such as cyclin G1, involved in G2/M arrest in response to DNA 
damage (S. Wang et al., 2012), RhoA, a member of the Rho family of small GTPases 
associated with tumor cell proliferation and metastasis (S. C. Wang et al., 2014), and BCL-w, 
an anti-apoptotic Bcl-2 family member (Lin, Gong, Tseng, Wang, & Wu, 2008). However, 
despite a lot of existing data on miR-122 and its association with tumorigenesis (Figure 3), a 
complete description of the miR-122-regulated target network, especially in metastasis 
remains incomplete. 
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Figure 3. The network of parts of the interactions between miR-122 and its main identified 
target genes (blue circles) for the regulation of HCV (Hepatitis C virus) replication (green 
circles) and tumor related processes (normally focus on hepatocellular carcinoma) (red and 
grey circles) (J. Chang et al., 2004; Hsu et al., 2016; Lin et al., 2008; Tsai et al., 2009; B. 
Wang et al., 2014; S. Wang et al., 2012; S. C. Wang et al., 2014). 
As a prelude to this project, the whole genomes of 12 patients with advanced colorectal 
cancer were sequenced with the Illumina next generation sequencing platform at the Allgayer 
department. Bioinformatics analysis and subsequent validation showed that the miR-122 gene 
locus was deleted in primary tumors and corresponding metastases of most patients. 
Interestingly, while the expression of miR-122 was suppressed in primary tumors, it was 
significantly increased in metastatic lesions. This, however, contrasted to the additional 
observation at the genome level. 
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2 AIM OF THE PROJECT 
The aim of this project was to investigate the role of miR-122 in colorectal cancer liver 
metastasis. The specific objectives were to: 
1) Identify putative targets of miR-122 that could play a role in metastasis 
2) Validate the identified targets with 3’UTR reporter gene assays and evaluate the specificity 
of the miRNA/target interactions 
3) Evaluate the impact of miR-122 on the expression of the identified targets  
4) Investigate the mechanisms of miR-122 activity in the context of liver metastasis 
5) Identify metastasis related functions impacted by miR-122 
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3 MATERIALS AND METHODS 
3.1 Materials 
3.1.1 Cell lines 
The RKO, CaCo2, SW48, SW480, SW620, HCT116, HT1080, DLD-1, Colo-320 (human 
colorectal), and 239T (mouse embryonic kidney) cell lines were obtained from the American 
Type Culture Collection (ATCC). The Huh7 and Hep3B cell lines were kind gifts from Drs. 
Rodriguez-Vita and Clemm von Hohenberg both of the German Cancer Research Center 
(DKFZ), respectively. The cell lines were maintained in the recommended media 
supplemented with 10% FBS. All cells were cultured in a humidified incubator at 37 °C with 
5% CO2. 
3.1.2 Plasmids 
Empty vector plasmid pLightSwitch 3’ UTR plasmid was purchased from SwitchGear 
Genomics (Menlo Park, USA). 
 
 
 
 
 
Figure 4. pLightSwitch 3’ UTR plasmid stucture 
http://switchgeargenomics.com/resources/vector-maps/3utr-reporter-vector 
3.1.3 Primers 
3’UTR cloning primers 
Gene name Gene symbol Forward primer (Tm [°C]) Reverse primer (Tm [°C]) 
Regulating synaptic RIMS1 AATATGCTAGCTGAACTCATAC CCGCGCTCGAGGACATGAA
AAGTAAATTTTATTAAA 
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membrane exocytosis 1 CAGAGTCATTCCAA (72.1) (70.9) 
RAB, member RAS 
oncogene family-like 6 
RABL6/C9orf86 ATTAATGCTAGCGCCGGCGTGG
GCAGTGGCCGCCCTG (84.6) 
GCCGGCCTCGAGCAGAGTG
AAACAGGAGTGCTTTATG 
(80.1) 
ABL proto-oncogene 1, 
non-receptor tyrosine 
kinase 
ABL1 
TTAATTAGCTAGCCAGCAGTCA
GGGGTCAGGTGTCAGG (79.1) 
CCGGCCGCTCGAGCTAATG
TAAACACTGATTTATTTAA 
(74.5) 
G protein-coupled 
receptor kinase 
interacting ArfGAP 1 
GIT1 
AATTAGCTAGCCCTCTCTCCCC
ACACCCTCACCTGC (79.9) 
GGCCGCTCGAGAACAGCTC
ATGGTCACTTCTTTATT 
(76.6) 
Growth factor receptor-
bound protein 7 
GRB7 
TTAAATTAGCTAGCCCAGGCCG
TGGACTGGCTCATGCCT (80.0) 
GGCCCGGCCTCGAGGTATC
AAAAAATAATCTTTATTGT
C (75.9) 
Integrin, alpha L  ITGAL 
AATTAGCTAGCGTCCAGGCCTG
TGAGGTGCAGAGTG (79.1) 
GGCCGCTCGAGGGACAGA
ATTTCACATTTATTGGAT 
(75.4) 
 
Site-directed mutagenesis primers: 
Gene 
symbol 
 Forward primer (Tm [°C]) Reverse primer (Tm [°C]) 
RIMS1 1 cagaaatgtgtagaatacaacttttcacatctgtagagtttcc
agtttgttcaatttggtgtgtgtgtgt (78.19) 
acacacacacaccaaattgaacaaactggaaactctacag
atgtgaaaagttgtattctacacatttctg(78.19) 
 2 Catttttttaatatcaggaagaaaaaggcattacaagtctgtt
tttcaaagtacaattatgcagttagttttagtcccca 
(78.09) 
Tggggactaaaactaactgcataattgtactttgaaaaaca
gacttgtaatgcctttttcttcctgatattaaaaaaatg 
(78.09) 
 3 Atgctgctctatttgtgtaatcacaaaagtgtctgtactcata
aaaggagggagaacatatcaatgc (78.04) 
Gcattgatatgttctccctccttttatgagtacagacactttt
gtgattacacaaatagagcagcat (78.04) 
 4 Attggaatttcatttaaaagcacagggtctgtttaagacaag
tggtcaaaatagaaagatactacccaattataatcag 
(78.56) 
Ctgattataattgggtagtatctttctattttgaccacttgtctt
aaacagaccctgtgcttttaaatgaaattccaat (78.56) 
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RABL6/
C9orf86 
1 Ctgagtggagtgtttgggagtctgtcctcccggctcctgcc
ttcg (79.08) 
Cgaaggcaggagccgggaggacagactcccaaacact
ccactcag (79.08) 
 
2 Ggagtgctttatggtctgagtgtctgttttgggagtctgtcct
cccggct (78.50) 
Agccgggaggacagactcccaaaacagacactcagac
cataaagcactcc (78.50) 
GIT1 
1 Tggggtggggattaatgtctgtctgtgcccagctcctatgg
ccagtg (78.31) 
Cactggccataggagctgggcacagacagacattaatcc
ccacccca (78.31) 
 
2 Acctggctgccaggtctgttggcagcactaagggcacttg
tgcca (78.17) 
Tggcacaagtgcccttagtgctgccaacagacctggcag
ccaggt (78.17) 
 
3 Aggcgaggggctggtctgtatgccttgcaggcccctgctc
act (78.97) 
Agtgagcaggggcctgcaaggcatacagaccagcccct
cgcct (78.97) 
 
4 Cggagagctgccccacttgtctgttccccacctgccccttt
gc (78.97) 
Gcaaaggggcaggtggggaacagacaagtggggcag
ctctccg (78.97) 
 
5 Aagttcatagagaaggggcgatctgtgggagggatcagg
gaggcagc (78.31) 
Gctgcctccctgatccctcccacagatcgccccttctctat
gaactt (78.31) 
GRB7 
1 Caaagaagcagaggagaaaactgtctgtgcggaaccctc
ccgctcctcatc (79.36) 
Gatgaggagcgggagggttccgcacagacagttttctcc
tctgcttctttg (79.36) 
 
2 Gagaggggtcaggagtggactgtctgtggggctgttttct
atctgaggg (79.28) 
Ccctcagatagaaaacagccccacagacagtccactcct
gacccctctc (79.28) 
 
3 Ttcccttgaggagaggggtcagtctgtgactgtctgtggg
gctgttttc (78.44) 
Gaaaacagccccacagacagtcacagactgacccctct
cctcaagggaa (78.44) 
 
RT-PCR primers 
RT-PCR primers were purchased from QIAGEN; RIMS1 (Cat# QT01016673), RABL6 (Cat# 
QT00105042), and for internal control B2M (Cat# PAHS-000Z), RRN18S (Cat# 
QT00199367). The primers for miRNAs were also purchased from QIAGEN; miR-122 (Cat# 
MS00003416) and for internal control RNU6-2_11 (Cat# MS00033740). 
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3.1.4 miRNA mimics and inhibitors 
miR-122 mimic and inhibitor were purchased from from Ambion, Life Technologies (miR-
122 mimic ID: MC11012 and inhibitor ID: MH11012). 
3.1.5 Antibodies 
Primary antibodies 
Antibody anti- Species/isotype Dilution for WB Supplier 
RIMS1 IgG Rabbit 1:5000 Alomone labs 
RABL6 IgG Rabbit 1:5000 ThermoFisher 
β-actin IgG Rabbit 1:10000 Abcam 
 
Secondary antibodies 
Antibody anti- Dilution for WB Supplier 
Rabbit IgG 
Mouse IgG 
1:10000 
1:10000 
Cell Signaling 
Cell Signaling 
 
3.1.6 Kits 
Products Supplier 
QIAamp
®
 DNA Mini kit QIAGEN 
miScript II RT Kit QIAGEN 
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Qiaquick® Gel Extraction Kit 
Qiaquick® PCR Purification Kit 
QIAprep® Spin Miniprep Kit 
QIAGEN 
QIAGEN 
QIAGEN 
miRNeasy® Mini Kit QIAGEN 
exoEasy Maxi Kit QIAGEN 
exoRNeasy Serum/Plasma Starter Kit 
CellTiter 96® Aqueous One Solution 
Cell Proliferation Assay 
QIAGEN 
Promega 
 
3.2 Methods  
3.2.1 Cell culture 
Cells were cultured routinely in T25 flasks at 37°C in the presence of 5% CO2 and 90% 
humidity. Culture media were cell line specific (Gibco GmbH, Germany) and supplemented 
with 10% FBS (Sigma-Aldrich). Depending on growth rate, cells were passaged as necessary. 
The routine procedure consisted of washing the cells with PBS (Gibco GmbH, Germany) and 
adding trypsin (Gibco GmbH, Germany) to cover the cells, followed by a 3-5 min short 
incubation at 37°C to aid detachment. The cells were then observed under a microscope to 
confirm detachment. A minimum of 3 volumes in excess of trypsin, of complete medium 
(with FBS) was added to the cells, pipetted up and down several times to ensure a single cell 
suspension, centrifuged to remove excess trypsin, re-suspended in medium and distributed 
into new flaks in the required dilution and topped up with medium requisite of the flask. 
3.2.2 Co-culture 
Huh7 cells were plated in the bottom of 12mm Transwell® with 0.4µm Pore Polyester 
Membrane Insert (Costar) 2 days before RKO cells. Each well contains 200,000 Huh7 cells 
initially. RKO cells were plated into the top small well 2 days later for 100,000 cells per well. 
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After 48 or 72 hours, total RNA of RKO cells in the top well was collected by miRNeasy® 
Mini Kit (QIAGEN).  
3.2.3 Transfection 
Two different colorectal cancer cell lines (HCT116 and RKO) were used for transfection with 
miRNA-mimics, -inhibitors, and their corresponding scrambled controls. Mimics and 
inhibitors were transfected at a final concentration of 150 nM using the METAFECTENE® 
(Biontex Laboratories GmbH). The cells were incubated for 24–72 hours following 
transfection before proceeding with experiments. 
3.2.4 RNA Isolation  
Total RNA including miRNA was extracted and purified from cell lines using Qiagen’s 
miRNeasy Mini Kit according to the manufacturer’s protocols. The cells were disrupted by 
adding 700 µl QIAzol Lysis Reagent (GIAGEN) and pipetting to mix. The lysate was 
transferred into a microcentrifuge tube. Then the tube was placed on the benchtop at room 
temperature (15–25°C) for 5 min. 140 µl chloroform was added into the tube and shake the 
tube vigorously for 15 s. Place the tube on the benchtop at room temperature for 2–3 min. 
Centrifuge for 15 min at 12,000 x g at 4°C.  After centrifuge, the upper aqueous phase in the 
tube was transferred to a new collection tube. 1.5 volumes (usually 525 µl) of 100% ethanol 
was added and mix thoroughly by pipetting up and down several times. The sample was 
added into an RNeasy Mini spin column in a 2 ml collection tube (supplied in the kit) and was 
centrifuged at ≥8000 x g (≥10,000 rpm) for 15 s at room temperature(15–25°C). The flow-
through was discarded. 700 µl Buffer RWT was added to the RNeasy Mini spin column and 
centrifuged for 15 s at ≥8000 x g (≥10,000 rpm) to wash the column. 500 µl Buffer RPE was 
added onto the RNeasy Mini spin column and centrifuged for 15 s at ≥8000 x g (≥10,000 
rpm). Another 500 µl Buffer RPE was added to the RNeasy Mini spin column and centrifuged 
for 2 min at ≥8000 x g (≥10,000 rpm) to dry the RNeasy Mini spin column membrane. In the 
end, 30–50 µl RNase-free water was added directly onto the RNeasy Mini spin column 
membrane and centrifuge for 1 min at ≥8000 x g (≥10,000 rpm) to elute the RNA. RNA can 
be stored at -80°C. The concentration of RNA was measured by NanoDrop™ 2000 
Spectrophotometer (ThermoFisher). 
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3.2.5 DNA Isolation 
Genomic DNA was extracted with the QIAamp
®
 DNA Mini kit from 293T cell line according 
to the given protocol. In summary, cell pellets were re-suspended in 200 µl PBS and 200 µl 
Buffer AL was added to the sample. Mix by pulse-vortexing for 15 s. The mixture was 
incubated at 56°C for 10 min. 200 µl ethanol (96–100%) was added to the sample, and pulse-
vortexed for 15 s. After mixing, the mixture was applied to the QIAamp Spin Column and 
centrifuged at 6000 x g (8000 rpm) for 1 min. 500 µl Buffer AW1 was added then and 
centrifuged at 6000 x g (8000 rpm) for 1 min. 500 µl Buffer AW2 was added and centrifuged 
at full speed (20,000 x g; 14,000 rpm) for 3 min. 200 µl Buffer AE or distilled water was 
added. Incubate at room temperature (15–25°C) for 1 min, and then centrifuge at 6000 x g 
(8000 rpm) for 1 min. The products can be stored at -20°C. The concentration of DNA was 
measured by NanoDrop™ 2000 Spectrophotometer (ThermoFisher). 
3.2.6 Reverse Transcription (cDNA synthesis) 
Reverse transcription was performed to obtain the cDNA from RNA. Cell line RNA samples 
were thawed on ice. We used miScript II RT Kit (QIAGEN) and chose 5 × miScript HiFlex 
Buffer for the reverse transcription. Assemble the following reaction in a sterile 
microcentrifuge tube and incubate at 37
0
C for 1 hour and 95
0
C for 5 min. After reverse 
transcription, cDNA was diluted 10× and stored at -20
0
C. 
Sample RNA                                                500ng 
5 × miScript HiFlex Buffer                              2µl 
10 × miScript Reverse Transcripttase Mix       1u 
10 × miScript Nucleics Mix                             1µl 
Rnase-Free Water                                        Variable 
Final volume                                                   10µl 
3.2.7 PCR for amplification of 3’UTR 
PCR setup for DNA from 293T cell line: 
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Term End Concentration Volume 
10 × Qiagen PCR buffer 1 × 1 μL 
Forward Primer 0.2 μM 0.2 μL 
Reverse Primer 0.2 μM 0.2 μL 
dNTPs 0.2 mM 0.2 μL 
Qiagen Tag DNA polymerase 0.5 unit/μL 0.1 μL 
Water 
 
Variable 
DNA template (100ng) 
 
Variable 
Total volume of reaction 
 
10 μL 
 
PCR setup for 3‘UTR cloning of MIR122 targets 
Gene Initial 
Denat. 
Denat. Annealing Extension Final 
Extension 
Cycles 
RIMS1 
94℃ 
3 min 
94℃ 
1 min 
 58℃ 45 sec 72℃ 2 min 
72℃ 
10 min 
35 
RABL6/C9orf86  55℃ 45 sec 72℃ 1 min 
ABL1  55℃ 45 sec 72℃ 90 sec 
GIT1  60℃ 45 sec 72℃ 30 sec 
GRB7  51℃ 45 sec 72℃ 2 min 
ITGAL 62℃ 45 sec 72℃ 2 min 
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3.2.8 Realtime-PCR 
Realtime-PCR was used to quantity miR-122 expression in different cell lines or cells under 
different interfering. Real-time PCR was performed using Fast SYBR™ Green Master Mix 
(Applied Biosystems™). All samples were normalized to the internal control (B2M or RNU6) 
and fold changes were calculated with the 2
-ΔΔCt
 method.  
Term End Concentration MIR122 RNU6 
Fast SYBR™ Green Master Mix 1 × 5 μL 5 μL 
10 × Primers 1 × 1 μL 1 μL 
Universal primer 0.5 μM 1 μL 1 μL 
Water 
 
1 μL 1 μL 
cDNA template (1:10 diluted) 
 
2 μL 2 μL 
Total volume of reaction 
 
10 μL 10 μL 
 
Term Final Concentration RIMS1 RABL6 B2M 
Fast SYBR™ Green Master Mix 1 × 5 μL 5 μL 5 μL 
10 × Primers 1 × 1 μL 1 μL 1 μL 
Water 
 
2 μL 2μL 2 μL 
cDNA template (1:10 diluted) 
 
2 μL 2 μL 2 μL 
Total volume of reaction 
 
10 μL 10 μL 10 μL 
 
3.2.9 Colony PCR 
Single colonies were picked and suspended in 100µl Milli-Q water. Meanwhile a regular PCR 
with pLightSwitch_3UTR plasmid primers (Forward: GGGAAGTACATCAAGAGCTTCGT; 
Reverse: CCCCCTGAACCTGAAACATAAA) and gel analysis were performed to verify the 
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insert DNAs. The correct ones were added into 5ml LB medium with Ampicillin respectively 
and shaken overnight at 37°C. QIAprep® Spin Miniprep Kit was used to extract and purify 
plasmids from E.coli (One Shot™ TOP10 Chemically Competent E. coli, Invitrogen™). Two 
to 3 clones of each 3‘UTR were sequenced to identify correctly cloned 3’UTRs.  
3.2.10 Plasmids 
The restriction sequences for the chosen restriction enzymes were already incorporated to the 
forward and reverse primers of the target genes of miR-122. The restriction digest reaction 
(Nhe I 10,000 u/ml and Xho I 20,000 u/ml, New England BioLabs) were assembled in a 
sterile microcentrifuge tube and incubated at 37°C for 1 hour. For the pLightSwitch, plasmid 
vector, 1ul of Shrimp Alkaline Phosphatase (SAP, 1 u/µl) (Fermentas) was added for 1 hour 
at 37°C after the digestion. The DNA products were purified with the Qiaquick® PCR 
Purification Kit according to the protocol as described in 3.2.14. 
DNA fragment or plasmid                         1000 ng 
Nhe I                                                                1 µl 
Xho I                                                                1 µl 
Cutsmart buffer                                                5 µl 
Nuclease-Free Water to final volume of        50 µl 
T4 DNA Ligase (5u/µl) (Fermentas) catalyzed the ligation of the amplified 3‘UTR fragments to the 
pLightSwitch_3’UTR plasmid after the digestion with NheI and XhoI I. A 3:1 molar ratio of vector: 
insert DNA was used as following:  
100ng vector × kb size of insert × 3 = ng of insert 
3.9 kb vector            1 
 
Assemble the following reaction in a sterile microcentrifuge tube and incubate at room 
temperature overnight.  
Vector DNA                                            100ng 
Insert DNA                                             Variable 
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Ligase 10X Buffer                                       1µl 
T4 DNA Ligase                                            1u         
Nuclease-Free Water to final volume of    10µl 
One Shot® TOP10 Chemically Competent E. coli (Invitrogen) were thawed on ice for half an 
hour. 10µl ligation reaction product was added into 50µl of competent cells and incubated on 
ice for 30 min. Then the cells were heat shocked for 45 sec at 42℃ and immediately placed on 
ice for 5 min. 500µl LB (Luria Broth) medium was added into each tube and incubated for 1 
hour at 37°C with vigorous shaking. The suspension was then applied on a LB agar plate 
containing Ampicillin. The plates were incubated overnight at 37°C. Single colonies were 
picked and then processed as in step 3.2.9. 
3.2.11 Site directed mutagenesis 
PCR set up for site directed mutagenesis 
10× reaction buffer                                                                           5 µl  
dsDNA template (plasmids in 2.2.9 verified by sequencing)         50 ng  
Oligonucleotide primer #1                                                            250 ng 
Oligonucleotide primer #2                                                            250 ng  
dNTP mix                                                                                          1 µl  
ddH2O to a final volume of                                                             50 µl 
1 µl of Pfu DNA Polymerase (native) (2.5 u/µl) (Fermentas) was added to sample reaction. 
The cycling parameters outlined in the following table 
Segment Cycles Temperature Time 
1 1 95°C 30 seconds 
2 12 95°C 30 seconds 
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55°C 1 mintute 
68°C 2 minutes/kb of plasmid length 
 
1 µl of the Dpn I restriction enzyme (10 u/µl) (BioLabs) was added after the cycles. Gently 
and thoroughly mix each reaction, spin down in a microcentrifuge for 1 minute, and 
immediately incubate at 37°C for 1 hour to digest the parental supercoiled dsDNA. 1 µl of the 
Dpn I-treated DNA was transfected into One Shot® TOP10 Chemically Competent E. coli as 
described previously in 3.2.10 and verified by sequencing. 
3.2.12 Agarose gel electrophoresis  
To validate the specificity of PCR products, gel analysis was performed. A 2% gel (3 g 
agarose powder dissolved in 150 mL 1 × TAE buffer) was used. For each sample analyzed, 10 
μL PCR product, 5 μL 2 × loading dye and 1.5 μL 10 × Midori Green (NIPPON Genetics 
EUROPE GmbH) were loaded into the gel. 5 μL DNA ladder (100bp) was then loaded 
alongside the samples. The gel was run at 110 V for 1 h. The presence of only 1 band in each 
lane supported the specificity of the reaction. 
3.2.13 Gel purification 
The QIAquick Gel extraction kit (QIAGEN) was used for this application. Gel slices 
containing the desired fragment were cut with a scalpel under UV light, transferred to an 
eppendorf tube and weighed. The gel was dissolved by heating the slice in 3 equivalent 
volumes (gel) of QG buffer for 10 minutes (or longer if dissolution was not achieved) at 50
o
C. 
One volume of the gel mass of isoproponal was added to the mixture, mixed properly, 
transferred into a QIAquick column and centrifuged for 1min at 13000 rpm. The flow-through 
was discarded and 500 µl of buffer QG was added to the column and centrifuged for 1 min at 
13000 rpm to remove the remaining traces of gel from the sample. Subsequently, 750 µl 
buffer PE was used to wash the column, which was centrifuged for an additional 1 min to 
remove the traces of the buffer. In between the steps the flow-through was discarded. The 
column was transferred into a fresh 1.5 ml eppendorf and the DNA eluted in 30 µl of elution 
buffer (EB). The eluate was quantified using the Nanodrop spectrophotometer and used 
directly or stored at -20
o
C until required.  
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3.2.14 Purification of PCR products 
The Qiaquick® PCR Purification Kit (QIAGEN) was used for this application. 5 volumes of 
Buffer PB were added to 1 volume of the PCR sample and mixed. The sample was applied to 
the QIAquick column and centrifuged for 30–60s. The flow-through was discarded. 0.75 ml 
Buffer PE was added to the QIAquick column and centrifuged for 30–60s. The flow-through 
was discarded and the QIAquick column placed back in the same tube. The column was 
centrifuged for an additional 1 min. Place QIAquick column. To elute DNA, 30 µl Buffer EB 
(10 mM Tris·Cl, pH 8.5) or water (pH 7.0–8.5) was added to the center of the QIAquick 
membrane placed in a clean 1.5 ml microcentrifuge tube, let to stand for 1 min, and then 
centrifuged for 1 min. The products were stored at -20°C. The concentration of DNA was 
measured with NanoDrop™ 2000 Spectrophotometer (ThermoFisher). 
3.2.15 Western Blot 
Cells were washed by PBS and added ice-cold RIPA buffer (200µl per well). Plates were kept 
on ice for 15 min. The cells were scraped into microfuge tubes and then spun at 12,000×g for 
20 min at 4
0
C. The supernatant was transferred to fresh tubes and a small volume removed 
(10µl) to perform a BCA protein assay. 30-60µg of each sample was mixed with a quarter 
volume of 4× Laemmli sample buffer. Protein lysates were boiled at 95℃ for 5 min and then 
centrifuged for 1 min.  
Western Blot was used for the detection of RIMS1 and RABL6 proteins. The samples were 
loaded into 10% SDS-PAGE gels. The gel was run for about one and half hour at 100 V. The 
transfer sandwich was assembled avoiding bubbles. The PVDF blot was on the cathode and 
the gel on the anode. The cassettes were placed in the transfer tank and the tank placed in an 
icebox. Since RIMS1 protein is bigger than 150KD, the transfer was run for 150-180 min at 
100 V. The blots were stained with Ponceau S solution to check the transfer quality and then 
washed with TBST. The blots were then blocked in 5% non-fat milk at room temperature for 
1 hour followed by overnight incubation in a primary antibody solution at 4℃. The blots were 
rinsed 3 times with TBST and incubated in the secondary antibody for 1 hour at room 
temperature. The blots were rinsed 3 times again after which ECL substrate was applied to the 
blots. Then move into a dark room with a safe light, place covered membrane in a film 
cassette with protein side facing up. Place X-ray film on top of membrane, and expose for 1 
minute. Exposure time can be increased to achieve optimal results, with light emission being 
most intense immediately after substrate incubation and significantly decreasing within 1 
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hour. For probing the beta actin protein control, stripping buffer was added to the same blots 
for 15 min at room temperature and then incubated them in beta actin primary antibody 
overnight. The rest of the protocol is the same as described above. 
3.2.16 Reporter Gene (Luciferase) Assay 
Luciferase assay was used for confirming the effect of miR-122 on the selected target gene 
3’UTRs. We plated 2×104 293T cells or colorectal cancer cells in quadruplicate in a 96-well 
plate with 200µl complete medium. The next day the cells were rinsed by PBS and transfected 
with either miR-122 mimic or negative control miRNA together with six different plasmids 
respectively in serum free medium (SFM) using METAFECTENE® (Biontex) transfection 
reagent. All miRNA mimics, inhibitors and corresponding negative controls were purchased 
from Ambion. Each well was transfected with 50nM miRNA or control miRNA, 100ng of 3’ 
UTR plasmid construct and 20ng of Firefly luciferase vector. 24 hours after the transfection, 
the cells were washed with PBS. After complete aspiration of the PBS, the Dual-Luciferase® 
Reporter Assay System from Pro mega was used as follows: 20µl of 1×passive lysis buffer 
was added to each well and the plate was placed on rotary shaker for 15 min at room 
temperature. Subsequently, 50µl of LAR was added and the Firefly luciferase activity was 
measured luciferase activity on the Infinite M200 Microplate reader (Tecan) machine. Then 
50µl of freshly constituted Stop & glo added and the Renilla luciferase activity was measured. 
The luciferase activity (Renilla/Firefly) in each well for each given UTR was calculated and 
the relative luciferase activity was obtained by normalizing to the corresponding control. 
3.2.17 Exosome isolation 
The exoEasy Maxi Kit was used for purifying exosomes from up to 16 ml of cell culture 
supernatant. Huh7 was cultured in normal DMEM media to 60-70% confluency. The cells 
were washed by PBS and serum free DMEM media was added. 2 days later, the media was 
collected and centrifuged for 30 min. 1 volume buffer XBP (from the kit) was added to 1 
volume of supernatant. The combination was mixed by gently inverting the tube 5 times. The 
sample/XBP mix was then added onto the exoEasy spin column and centrifuged at 500 x g for 
1 min. The flow-through was then discarded followed by the addition of 10 ml of buffer XWP 
and centrifugation at 5000 x g for 5 min. After discarding the flow-through, the spin column 
was transferred to a fresh collection tube. 400 μl Buffer XE was added to the membrane and 
allowed to sit for 1 min. The column was then centrifuged at 500 x g for 5 min to collect the 
eluate. The eluate was re-applied to the exoEasy spin column membrane and allowed to sit for 
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1 min and centrifuged again at 5000 x g for 5 min to collect the eluate.  The exosome 
containing eluate was stored at -20℃. 
The exoRNeasy Serum/Plasma Starter Kit was used for purification of total exosome-derived 
RNA. After the addition of 1 volume Buffer XBP to 1 volume of the supernatant and mixing 
as described earlier, the sample/Buffer XBP mix was added onto the exoEasy spin column 
and centrifuged for 1 min at 500 x g. The flow-through was discarded followed by the 
addition of 10 ml Buffer XWP and centrifugation for 5 min at 5000 x g to wash the column. 
The flow-through was discarded and the spin column transferred to a fresh collection tube. 
700 µl QIAzol reagent was added to the membrane and spun for 5 min at 5000 x g to collect 
the lysate which was transferred to a new microfuge tube. This tube was briefly vortexed and 
incubated at room temperature (15–25°C) for 5 min after which 90µl chloroform was added 
and shaken vigorously for 15 s. After 2–3 min of incubation, the tube was centrifuged at 
12,000 x g and 4°C for 15 min. The upper aqueous phase was transferred to a new collection 
tube. 2 volumes of 100% ethanol were added and mixed thoroughly by pipetting. The sample 
was transferred to an RNeasy MinElute spin column and RNA was isolated as described 
above. The concentration of RNA was measured by NanoDrop™ 2000 Spectrophotometer 
(ThermoFisher). 
3.2.18 Cell proliferation assay  
Cell proliferation was determined with CellTiter 96® AQueous One Solution Reagent which 
contained a novel tetrazolium compound [3-(4, 5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt; MTS (a)] and an 
electron coupling reagent (phenazine ethosulfate; PES). RKO, HCT116 and DLD1 cell lines 
were transfected with miRNA mimics, inhibitors or corresponding controls. 24 hours later, 
Cells were seeded in 96-well plates at a density of 2 × 10
3
 cells/well in a total volume of 100 
μl of medium with 10% FBS. Six replicates were made for each condition and each evaluated 
time point. 20 ul of CellTiter 96 was added to each well and the absorbance was measured 
using a microplate reader (TECAN Trading AG, Switzerland) at 490 nm over a period of 96 - 
120 hours. 
3.2.19 Colony formation assay 
RKO and HCT116 cells were transected with miRNA mimics, inhibitors or their 
corresponding controls. 16–18 hrs after transfection, cells were trypsinized and re-seeded at a 
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density of 400–600 cells/well in a 6 well plate and maintained in their corresponding media 
containing 10% FBS at 37 °C. After 7-10 days, the colonies could be watched by eyes. Then 
the cells were fixed with methanol and stained with 0.1% crystal violet for 15 min. The 
ensuing colonies were scanned and counted by ImageJ. 
3.2.20 Cell cycle assay 
The cell cycle was assessed using the propidium iodide assay followed by flow cytometric 
analysis. RKO, HCT116 and DLD1 Cells RKO and HCT116 cells were transected with 
miRNA mimics, inhibitors or their corresponding controls. Cells were trypsinized 48h after 
transfection, washed with PBS, fixed in 1 ml cold 70% ethanol (1× 10
6 
per ml), and incubated 
at -30 °C for at least 1 hour. Next cells were washed with 10ml PBS again, resuspended in 
1ml PBS, added RNase (final concentration 50 μg/ml) and incubated 30 minutes at 37 °C in 
the dark. Then cells were stained with propidium iodide (50 μg/ml) (Sigma-Aldrich Corp. 
Saint Louis, MO, USA) and analyzed by Fluorescence-activated cell sorting (FACS). The 
data obtained were analyzed using the FlowJo v10 software. 
3.2.21 Statistical Methods 
The differences between groups were statistically analyzed using two tailed unpaired and 
paired t–tests when dealing with independent (cell lines, before/after treatment) and 
dependent (tumor/normal patient) variables respectively. All experiments were carried out at 
least in triplicate and at least in three independent attempts. Calculations were made using 
Microsoft Excel. Data were considered to be statistically significant when p < 0.05 and 
represented graphically as p < 0.05 (*) and p < 0.01 (**).  
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4 RESULTS 
4.1 Metastasis associated genes are predicted targets of miR-122 
We used a combination of methods to explore putative novel oncogenic target mRNAs for 
miR-122. In the first approach, we looked for targets of miR-122 that had in one way or the 
other being implicated in metastasis. Through this function-based approach, RIMS1 and 
RABL6/C9orf86 were identified as the most significant hits. In the second approach, we 
pooled all of the predicted targets and put them into a pathway analysis tool. Using the 
Ingenuity Pathway Analysis (IPA) package, we identified and selected the Integrin pathway, 
which featured prominently in the output of significant pathways. The integrin pathway plays 
important roles in cancer invasion and metastases. The miR-122 targets in this pathway were 
ABL1, GIT1, GRB7, and ITGAL. The alignments of these 6 genes with miR-122 are shown in 
Figure 5. 
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Figure 5. The alignments of these 6 genes with miR-122. 
Retrieved from: http://www.microrna.org  
4.2 Amplification and cloning of 3’ UTRs in pLightSwitch 3’ UTR Vector 
To determine if these 6 genes were direct targets of miR-122, we first of all amplified the 3’ 
UTRs of RIMS1, RABL6/C9orf86, ABL1, GIT1, GRB7, and ITGAL from the genomic DNA of 
the human embryonic kidney 293T cell lines with PCR. The amplified fragments were 
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resolved on an agarose gel to find out if the correct fragment size(s) had been amplified 
(Figure 6). After digestion of the fragments with NheI and XhoI and ligation in the 
pLightSwitch 3’UTR plasmid, several colonies were picked and a colony PCR was done with 
pLightSwitch specific primers to identify the clones with the correct size of insert and 
orientation (Figure 7). The clones containing the right size of insert were Sanger-sequenced 
to confirm the insert.  
 
Figure 6. Agarose gel electrophoresis of PCR products of ABL1, RABL6/C9orf86, GRB7, RIMS1, 
ITGAL, and GIT1. 
 
Figure 7. Agarose gel electrophoresis of colony PCR for the identification of potentially correct 
clones. 
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4.3 3’ UTR Reporter gene assay identifies RABL6 and RIMS1 as significantly suppressed 
targets 
The cloned plasmids of all 6 3’UTRs were subjected to a reporter gene assay in 293T, RKO, 
SW480 and HT1080 cells transfected with a miR-122 mimic or corresponding control. Of the 
6 mRNAs, those of RIMS1 and RABL6 showed the most significant suppression in the 
presence of miR-122. Compared with the control miRNA, miR-122 significantly decreased 
the luciferase activity by 70.7 % in 3’ UTR of RIMS1 and 61.7% in RABL6 in 293T cells, 
which means miR-122 interacts with the 3′ UTR of RIMS1 and RABL6 (Figure 8). Similar 
results were obtained with RKO, SW480 and HT1080 cells. GRB7 showed some mild 
suppression, but no suppression was seen with GIT1, ABL1 and ITGAL (Figure 8).  
 
Figure 8. 3’ UTR relative luciferase activity of 6 potential target mRNAs following treatment with 
miR-122. 
4.4 Endogenous expression of miR-122 in colorectal and liver cell lines 
In order to determine which cell lines would be best suited for the evaluation of miR-122 
function, as well as over-expression and knock-down studies, we screened a panel of 
colorectal and liver cell lines for the endogenous expression of miR-122. The miR-122 
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expression was generally low in all the colorectal cancer cell lines screened. However, DLD1, 
SW480 and Caco2 showed the highest relative expression, while HT29, SW48 and SW620 
showed the lowest expression levels (Figure 9). Since miR-122 was shown to be highly 
expressed in hepatocytes, we decided to analyze its expression in two hepatocellular 
carcinoma cell lines (Huh7 and Hep3B). While the expression of miR-122 was low in Hep3B 
cells, it was very highly expressed in Huh7 cells (Figure 10).  
 
Figure 9. Cell line screening for the expression of miR-122 in a panel of colorectal cancer cell lines, 
graph shows expression relative to the RKO cell line after normalization to SNO68.  
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Figure 10. Cell line screening for the expression of miR-122 in colorectal cancer cell lines and 2 
hepatocarcinoma cell lines, graph shows expression relative to the RKO cell line after normalization to 
RNU6. 
4.5 miR-122 suppresses mRNA and protein expression of RABL6 and RIMS1 
To confirm the effect of miR-122 on the suppression of RIMS1 and RABL6 expression, we 
transfected RKO, DLD1 and HCT116 cells with miR-122 mimic or corresponding control. 
On the mRNA level, miR-122 led to a significant decrease of RIMS1 (P = 0.036348821) and 
also a trend of RABL6 decrease in RKO (Figure 11). Meanwhile there is a significant 
decrease of RABL6 in DLD1 (P= 0.003768173) although no decrease of RIMS1 (Figure 11). 
On the protein level by Western Blot, miR-122 also led to a decrease of RABL6 expression 
(Figure 12). Based on these results, we sought to demonstrate that these two genes are direct 
targets of miR-122. 
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Figure 11. RIMS1 and RABL6 mRNA expression following transfection with miR-122 in RKO & 
DLD1 cell lines.  
 
Figure 12. Assessment of RABL6 protein expression in RKO, HCT116 and DLD1 cells following 
transfection with miR-122 mimic, miR-122 inhibitor and oligonucleotides. 
4.6 miR-122 is secreted in the conditioned media and exosomes of Huh7 cells 
We hypothesized that since the metastatic lesions were in the liver, that miR-122 was 
acquired by the colorectal cancer cells from the liver parenchymal cells through paracrine 
activity. To prove this hypothesis, we analyzed the conditioned media of Huh7 cells for miR-
122 abundance relative to control serum free media. Additionally, we checked to see if any 
extra-cellular miR-122 was present in the exosomal fraction of the conditioned media. RNAs 
were purified from conditioned media (no FBS DMEM media) of Huh7 cells as previously 
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described. From 16 ml media, the RNA concentration was about 150ng/μl compared to 0ng/μl 
in fresh media. Real-time PCR was used to amplify miR-122 in total exosomes (Figure 13). 
 
Figure 13. The expression of miR-122 in exosomes extracted from conditioned media of Huh7 cells. 
4.7 Huh7 Liver cancer cells are able to transfer miR-122 to colorectal cancer cells in co-
culture, through conditioned media and exosomes 
 After confirming that miR-122 was secreted into the conditioned media and was present in 
exosomes, we proceeded to find out if these miRs could be taken up by colorectal cancer 
cells, in a situation similar to what we had observed in the patient samples. Towards this end, 
Huh7 cells were cultured with RKO cells (Huh7 cells were plated 2 days before RKO cells as 
described in 2.2.2). After 3-5 days of co-culture, total RNA from RKO cells in the top well 
was collected and real-time PCR was performed to measure miR-122 expression. From the 
third day, we observed an increase of miR-122 expression in RKO cells. Moreover, this 
expression was still significantly enhanced on the fourth day and fifth day relative to control 
cells (Figure 14), which means RKO cells could take up miR-122 secreted from Huh7 cells. 
To further confirm that this transfer was from exosomes, we directly added the exosomes 
extracted from conditioned media of Huh7 into normal medium of RKO and HCT116 cells, 
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using the buffer for exosomes in the kit as the negative control. The miR-122 expression was 
significantly upregulated in RKO however only a slightly upregulated in HCT116 (Figure 15).  
 
Figure 14. The expression of miR-122 in the RKO cell line co-cultured with the Huh7 cell line after 3 
days, 4 days and 5 days.  
 
Figure 15. The expression of miR-122 in RKO & HCT116 cells treated with exosomes extracted from 
Huh7 conditioned media. Exosome elution buffer was used as a negative control. 
4.8 Liver cell exosomes mediate suppression of target genes in colorectal cancer cell lines 
To further confirm if RIMS1 and RABL6 could be targeted by miR-122 from exosomes, we 
directly added exosomes extracted from conditioned media of Huh7 into normal medium of 
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RKO, HCT116 and DLD1 cells, and the exosome elution buffer as a negative control. On the 
mRNA level, miR-122 led to a significant decrease of RIMS1 in all three cell lines and a 
significant decrease of RABL6 in RKO and DLD1 cells. Moreover, we also observed a trend 
of decreased expression of RABL6 in HCT116 (Figure 16).  
 
Figure 16. RIMS1 and RABL6 mRNA expression in RKO, HCT116 & DLD1 cell lines following 
treatment with exosomes extracted from Huh7 cell conditioned media. Exosome elution buffer was 
used as a negative control. 
4.9 Cell cycle genes are downstream effectors of RABL6 and are suppressed by miR-122 
Since RIMS1 and RABL6 expression could be suppressed by miR-122 in colorectal cancer cell 
lines, we tried to assess the effects of miR-122 not only on its direct targets, but also on 
related signaling molecules. Although there are few reports about RIMS1, the cumulative data 
suggests that RABL6 might be an important regulator for cell proliferation and G1-S transition 
(Hagen et al., 2014; Tang et al., 2016). We also found miR-122 upregulated cyclin-dependent 
kinase inhibitor 1A (CDKN1A, P21) expression in both RKO and HCT116 cell lines (Figure 
17), which is a classical cell cycle checkpoint inhibitor protein. These results suggest that 
miR-122 induced suppression of RABL6 caused P21 upregulation.  
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Figure 17. Assessment of P21 protein expression in RKO and HCT116 cells following transfection 
with miR-122 mimic, miR-122 inhibitor and oligonucleotides. 
4.10 Targeting of RIMS1 and RABL6 suppresses tumor cell proliferation and colony 
formation 
To explore the function of RIMS1 and RABL6, RKO, HCT116 and DLD1 cells transfected by 
miR-122 and its inhibitor were subjected to cell proliferation and colony formation assays. 
The cell proliferation assay was evaluated over a 4 or 5-day time period. Although there was 
no significant difference in RKO cells, we observed a significant decrease in cell proliferation 
in HCT116 and DLD1 cells in which miR-122 had been over-expressed, and a corresponding 
increase in HCT116 cell with miR-122 inhibitor (Figure 18). Additionally, RKO, HCT116 
and DLD1 cells transfected by miR-122 and its inhibitor were analyzed by flow cytometry. 
We observed that a slightly higher amount of cells transfected with miR-122 arrested in the 
G0/G1 phase comparing to controls nearly in all cell lines at both 48h and 72h except in 
HCT116 at 72h (Figure 19). These results suggested a potential role for miR-122 in 
regulating the G1/S transition by targeting RABL6 and regulating P21. 
Similarly, colony formation assays showed significantly fewer colonies with the transfection 
of miR-122 mimics compared to controls in both RKO and HCT116 cells (Figure 20). The 
converse was observed with the miRNA inhibitors. This result further supports miR-122 as an 
inhibitor of cell proliferation by suppressing RABL6 expression. 
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Figure 18. Cellular growth curves of RKO, HCT-116 and DLD1 cell lines at 24 hours following 
transfection with miR-122 mimic, miR-122 inhibitor or control oligonucleotides.
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Figure 19 (A). Cell cycle analysis of RKO, HCT116 and DLD1 cells transfected with miR-122 
mimics, inhibitors or corresponding controls. The graph shows the relative percentages of cells in the 
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different phases of the cell cycle (G0/G1 vs S vs G2/M) and how these are affected by miR-122 mimic 
and inhibitor treatment. 
  Control miR-122 miR-122 inhibitor 
48h %G0/G1 RKO 55.4% 56.2% 47.6% 
 %G0/G1 HCT116 50.2% 54.6% 51.6% 
 %G0/G1 DLD1 57.6% 67.2% 65.1% 
72h %G0/G1 RKO 48.8% 51.6% 63.3% 
 %G0/G1 HCT116 58.6% 58.2% 62.9% 
 %G0/G1 DLD1 59.6% 65.5% 57.7% 
Figure 19 (B). Tabular representation of the cell cycle analysis in RKO, HCT116 and DLD1 cells 
transfected with miR-122 mimics, inhibitors or corresponding controls. The percentage of cells in 
G0/G1 phase is increased by the miR-122 mimic. 
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Figure 20. Colony formation assays performed with RKO and HCT116 cells. The cell lines were 
treated with miR-122 mimics, inhibitors or corresponding controls. (a) Representative examples of the 
scanned plates. (b) Overall quantification of the colonies conducted in ImageJ. Details are as described 
in the Materials and Methods. 
4.11 Targeting of RIMS1 and RABL6 might not affect tumor cell migration and 
invasion  
Since RABL6 and P21 were identified as important regulators for cell proliferation and G1-S 
transition, we also wanted to know if they could affect tumor cell migration or invasion. 
RKO, HCT116 and DLD1 cells transfected by miR-122 and its inhibitor were subjected to 
cell migration or invasion assays. Unfortunately, there was only one significant case of DLD1 
a 
b 
 44 
 
cells enhancing invasion following miR-122 inhibitor transfection (Figure 21). There was no 
significant difference in other cells.  
 
 
Figure 21. Invasion and migration assays in DLD1, HCT116 and RKO cells transfected with miR-122 
mimics, inhibitors or corresponding controls. 
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5 DISCUSSION 
Metastasis continues to be the major factor impacting prognosis and survival of colorectal 
cancer patients. Metastasis itself is not a single process but rather, a constellation of multiple 
events that culminate with the colonization of distant sites by the primary tumor. A number of 
published reports seem to indicate that the events playing in different metastatic sites are not 
identical and every metastatic niche is inherently different. In colorectal cancer, as well as 
several other solid tumors, the liver is a common site for metastasis. Decrypting novel 
molecular regulators modulating CRC metastasis will help to further understand CRC 
biology, and may provide potentially efficient targets for CRC therapy. 
The adaptation of tumor cells to a foreign microenvironment is critical to successful 
metastatic colonization (McGowan, Kirstein, & Chambers, 2009; Peinado, Lavotshkin, & 
Lyden, 2011; Talmadge & Fidler, 2010). This has been described as a highly inefficient 
process with circulating tumor cells trying to overcome many obstacles to colonize distant 
organs. These events include infiltrating distant tissue, evading immune defenses, adapting to 
supportive niches, surviving as latent tumor-initiating seeds and eventually breaking out to 
replace the host tissue (Massague & Obenauf, 2016). Despite immune defenses, there are 
some supportive niches that cancer cells can benefit from. Evidence exists that primary 
tumors can send systemic signals to influence the microenvironment of distant organs by 
creating pre-metastatic niches before the arrival of cancer cells (McAllister & Weinberg, 
2014). 
 After colonization, most metastasized cells enter a state of dormancy, of which two modes 
have been described. Tumor mass dormancy, in which micrometastases stop growing because 
of insufficient vascularization or constant culling by immune defenses; and cellular 
dormancy, where isolated disseminated tumor cells enter a proliferative quiescence state 
(Sosa, Bragado, & Aguirre-Ghiso, 2014). Which of the two modes is more frequent is 
uncertain (Strauss & Thomas, 2010), but it has been postulated that DTCs might enter the cell 
cycle intermittently, and undergo rapid elimination by the immune system. But in the end, 
some progeny will evolve the ability to escape immune defenses and develop overt metastatic 
lesions. There is increasing evidence suggesting that microRNAs are major players in all the 
steps of the metastasis cascade. 
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miRNAs are important metastasis molecules 
In an effort to better understand the molecular events at play in colorectal cancer liver 
metastasis, Prof. Allgayer’s department sequenced the whole genomes of 12 patients with 
advanced colorectal cancer. Other studies have also compared different primary tumors with 
their corresponding metastasis in the search for molecular mediators of metastasis, but in most 
cases looking for specific miRNAs or sequences. In some these studies, the pattern of some 
miRNA expression could distinguish primary tumors from their corresponding metastases, 
confirming a direct involvement of miRNAs in cancer metastasis, e.g. miR-10b, miR-21, 
miR-30a, miR-30e, miR-125b, miR-141, miR-200b, miR-200c, and miR-205 (Baffa et al., 
2009). In several studies, including work of the Allgayer team, a number of miRNAs were 
found to participate in different processes of metastasis by modulating the expression of genes 
involved in metastasis-related pathways and signaling networks, such as the phosphatase and 
tensin homolog (PTEN)/phosphatidylinositol-3-kinase (PI3K), EGF receptor (EGFR), TGFβ, 
and p53 pathways (Fish et al., 2008). In a further example, the loss of miR-200c expression 
was found to induce an aggressive, invasive, and chemoresistant phenotype by repressing E-
cadherin in non-small lung cancer (Ceppi et al., 2010).  
Interestingly, increasingly more key signaling pathways implicated in metastatic colon cancer 
that are targeted by microRNAs, are being identified. For instance, EGFR, a receptor tyrosine 
kinase (RTK) has been shown to involved in CRC progression and metastasis, and a handful 
of anti-EGFR agents, including tyrosine kinase inhibitors (TKIs) and monoclonal antibodies 
against EGFR (Giampieri et al., 2013) have been developed. However, most anti-EGFR 
targeted agents are frequently susceptible to drug-resistance. Increasing evidence has 
demonstrated that certain miRNAs correlate with drug resistance to anti-EGFR agents, and 
depending on whether the correlation is positive or negative, inhibitors or mimics can be used. 
For example, a combination of miR-7 and cetuximab, a monoclonal antibody against EGFR 
could enhance the growth inhibitory effect as compared to each agent alone (Suto et al., 2015). 
A miRNA profiling analysis in metastatic colorectal cancer (mCRC) patients treated with 
anti-EGFR monoclonal antibodies identified the let-7c/miR-99a/miR-125b miRNA cluster as 
a signature associated with an outcome different from that of anti-EGFR therapies, and this 
miRNA cluster may be used for the selection of patients with KRAS wild-type mCRC as 
good candidates for anti-EGFR therapy (Cappuzzo et al., 2014).  Moreover, miRs-134 and -
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370 were identified as tumor suppressor miRNAs that could suppress colorectal cancer 
tumorigenesis by regulating the EGFR signaling cascade (El-Daly et al., 2016). 
The miR-17-92 cluster is composed of six miRNAs (miR-17, -18a, -19a,-20a, -19b-1, and -
92a-1) was the first to be demonstrated as oncogenic (He et al., 2005).Consistent with its 
oncogenic role, the miR-17-92 cluster is upregulated in a variety of cancers including 
lymphomas (He et al., 2005; Rinaldi et al., 2007), lung cancers (Matsubara et al., 2007), and 
others (Volinia et al., 2006).  
miR-21 is one the most extensively studied miRNAs. It is upregulated in almost all kinds of 
cancers. It is transcriptionally activated by signal transducer and activator of transcription 3 
(Stat3) (Loffler et al., 2007) and also by CD24 expression of via SRC (Muppala et al., 2013). 
miR-21 was found to promote invasion, intravasation, and metastasis by downregulating 
Pdcd4 (Asangani et al., 2008). It also promotes cell motility and invasion by directly targeting 
PTEN (phosphatase and tensin homolog), a tumor suppressor known to inhibit cell invasion 
by blocking the expression of several matrix metalloproteases (Meng et al., 2007). 
The miR-34 family (miR-34a, b and c) are induced by p53 and are downregulated in several 
tumors such as non–small cell lung cancers (Bommer et al., 2007) and pancreatic cancers (T. 
C. Chang et al., 2007). However, reduction of the miR-34s is not always correlated with p53 
loss, suggesting a p53-independent mechanism of miR-34 reduction in some cancers. The 
oncoproteins CD24 and SRC are both downregulated by miR-34a (Muppala et al., 2013).  
Recently, miR-224 expression was observed to consistently increase with tumour burden and 
microsatellite stable status in colorectal cancer. miR-224 was found to enhance CRC 
metastasis in vitro and in vivo, by directly targeting SMAD4 (Ling et al., 2016). 
The APC gene is one of the first to be lost in CRC and its loss was found to trigger the 
overexpression of miR-135b through PTEN/PI3K pathway deregulation, and SRC 
overexpression resulting in tumor transformation and progression. In CRCs, miR-135b 
overexpression correlated with tumor stage and poor clinical outcome and the inhibition of 
this miRNA in CRC mouse models reduces tumor growth by controlling genes involved in 
proliferation, invasion, and metastasis. (Valeri et al., 2014). 
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Lately, miR-551a and miR-483 were identified as robust endogenous suppressors of liver 
colonization and metastasis. These miRNAs convergently targeted creatine kinase, brain-type 
(CKB), which routinely contributes to the generation of phosphocreatine. CKB is released 
into the extracellular space by metastatic cells encountering hepatic hypoxia and catalyzes 
production of phosphocreatine that is used to generate ATP, fueling metastatic survival (Loo 
et al., 2015).  
The epithelial to mesenchymal transition is often considered as an integral step in metastasis. 
The hallmark of EMT is the downregulation of the E-cadherin protein. The loss of miR-200c 
expression was found to induce an aggressive, invasive, and chemoresistant phenotype by 
repressing E-cadherin in non-small lung cancer (Ceppi et al., 2010). Also, miR-30a could 
inhibit invasion and metastasis, and was downregulated in non-small lung cancer by targeting 
Snai1 which was a known transcriptional repressor of E-cadherin and modulator of epithelial-
to-mesenchymal transition (EMT) (Kumarswamy et al., 2012). Moreover, in a systematic 
approach looking for metastatic drivers in colorectal cancer, three miRNAs, miR-218, miR-
135b, and miR-210, were identified as key molecules of an EMT-regulating network acting 
through a number of novel targets including SIAH1, SETD2, ZEB2 and especially FOXN3, 
which suppressed the transcription of N-cadherin. The modulation of N-cadherin impacted on 
the migration, invasion and metastasis of cancer cells (Mudduluru et al., 2015). Taken 
together, miRNAs are potent regulators of metastasis controlling migration, invasion, 
intravasation, EMT, metastatic colonization and even ATP generation in metastasis sites. 
 
miR-122 abates colorectal cancer metastasis 
Bioinformatics analysis and subsequent validation of our whole genome sequencing generated 
data showed that the miR-122 gene locus was deleted in primary tumors and corresponding 
metastases of most patients. Interestingly, while the expression of miR-122 was suppressed in 
primary tumors, it was significantly increased in metastatic lesions (Mudduluru et al., 2015). 
This suggested that the loss of miR-122 was needed to foster metastatic dissemination, but 
was again needed for colonization.  
The altered expression of miR-122 has been observed in hepatocellular carcinoma, viral 
hepatitis and hepatic ﬁbrosis. Several studies demonstrated the role of miR-122 in 
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hepatocellular carcinoma by investigating human tissue, plasma and serum samples as well as 
cell lines (Coulouarn et al., 2009; Koberle et al., 2013; Tsai et al., 2009). A study by Iino et al. 
revealed that the most abundant miRNA in liver metastasis compared with primary tumors of 
CRC was miR-122 (Iino et al., 2013). Another study by Carter et al. measured plasma 
samples of non-metastatic and metastatic colon cancer patients. They found that increased 
miR-122 levels were associated with a ‘bad’ prognostic subtype in metastatic CRC and also in 
non-metastatic CRC patients resulting in shorter relapse-free survival (RFS) and overall 
survival (OS) times (Carter et al., 2016).  
Exosomes mediate paracrine activity of miR-122 
In our experiments, the expression of miR-122 in metastatic lesions was surprisingly very 
high despite the deletion of the miR-122 gene locus in the metastatic lesions. This paradoxical 
finding has never been reported before. Also, no reports had figured out the mechanism of 
miR-122 expression aberrations in colorectal cancer cells. Since the liver is rich in miR-122, 
we postulated that a paracrine mechanism could be involved in the transfer of miR-122 to the 
metastasized colorectal cancer cells. Consistently, our results showed that miR-122 
expression was low/absent in all the colorectal cancer cell lines screened, whereas it was very 
highly expressed only in Huh7 cells, a hepatocellular carcinoma cell line.  
Extracellular factors can affect miRNA expression of normal and cancer cells and miRNAs 
can also be directly transported to the extracellular space and to other cells through exosomes 
(Gibbings, Ciaudo, Erhardt, & Voinnet, 2009). A substantial amount of research has been 
done in order to understand exosome-mediated cell–cell communication mechanisms. Various 
facets of material transport across biological membranes and the role of exosomes in disease 
development have been revealed. In fact, every type of protein, RNA (including miRNAs), 
(Vinciguerra & Stutz, 2004), breakdown product of signaling pathways and even viruses can 
be transported through exosomes (Fevrier, Vilette, Laude, & Raposo, 2005).  
Exosome-mediated miRNA transfer has been established as a mechanism of regulating 
intercellular communications (Valadi et al., 2007). Koga and colleagues demonstrated that 
exosomes or cellular membrane could prevent RNase from degrading miRNAs inside the 
exosome or cells, even in a dreadful condition, as in feces (Koga et al., 2011). Their study 
proved that miRNA integrity and function were maintained in an exosomal cushion when 
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transferred to distant sites. Since then, many groups revealed the potential use of exosomal 
miRNAs for diagnostic and prognostic purposes in lung (Zhou et al., 2017), prostate (Russo et 
al., 2012), ovarian (Li et al., 2017), breast (Yuan et al., 2012), colon (Hosseini et al., 2017), 
leukemia (Prieto et al., 2017), and other types of cancer. Moreover, exosome-secreted 
miRNAs have been shown to induce a number of biological functions including modulation 
of immune response and modulation of proteases, adhesion molecules, chemokine ligands, 
cell cycle and angiogenesis-promoting genes, and genes engaged in oxidative stress response. 
For instance, it has been showed that exosome-secreted oncogenic miRNAs enhance the 
invasive potential of breast cancer cell lines (Yang et al., 2011).  
In this project, we found that miR-122 was secreted in the conditioned media and exosomes 
of Huh7 cells, which means that miR-122, could be transferred extracellularly through 
exosomes.  Consistently, several reports also demonstrated that miR-122 could be detected in 
patients’ serum exosomes (Selmaj et al., 2017). Furthermore, we observed an increase of 
miR-122 expression in RKO cells from the third day of co-culture with Huh7 cells. This 
expression was still significantly enhanced on the fourth and fifth days. On the other hand, 
miR-122 expression was significantly upregulated in RKO and DLD1 cells when we directly 
added the exosomes extracted from conditioned media of Huh7 cells into their normal 
medium respectively. These two approaches both demonstrated that colorectal cancer cells 
could take up miR-122 secreted from Huh7 cells. This explains our previous paradoxical 
finding and elucidates where the overexpression miR-122 came from. To date, there are no 
reports about an exosomal interaction involving the delivery of miR-122 to colorectal cancer 
cells. However, the transfer of miR-122 via exosomes was documented to occur between 
human hepatoma cells, Huh7 and HepG2, grown in co-culture. In a reciprocal process, HepG2 
secreted Insulin-like Growth Factor 1 (IGF1) that decreased miR-122 expression in Huh7 
cells while exosomal miR-122, expressed and released by Huh7, could reduce growth and 
proliferation of recipient HepG2 cells (Basu & Bhattacharyya, 2014). A study by Lou et al. 
also showed that adipose tissue-derived mesenchymal stem cells (AMSCs)-derived exosomes 
could deliver miR-122 into hepatocellular carcinoma cells in vitro and altered miR-122-target 
gene expression, thereby rendering cancer cells sensitive to chemotherapeutic agents through 
an alteration of miR-122-target gene expression in hepatocellular carcinoma cells (Lou et al., 
2015). In addition, miR-122 was highly secreted by breast cancer cells into extracellular 
vesicles, including exosomes, and mechanistically suppressed glucose uptake by niche cells in 
vitro and in vivo by downregulating the glycolytic enzyme pyruvate kinase (PKM) (Fong et 
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al., 2015). Interestingly, the studies of Basu & Bhattacharyya and Lou et al., and other studies 
about hepatocellular carcinoma, showed that miR-122 secreted from hepatoma cells or 
hepatocellular carcinoma cells, could repress target mRNAs, thereby reducing growth and 
proliferation of recipient cells. This means that in the liver, miR-122 plays a role as a tumor 
suppressor in most cases. In the study by Fong et al., the authors found that although miR-122 
reduced primary tumour growth, it also facilitated metastasis by increasing nutrient 
availability in the pre-metastatic niche, and in vivo inhibition of miR-122 restored glucose 
uptake in distant organs and decreased the incidence of metastasis. In this case, miR-122 
could promote metastasis.  
Molecular mediators of miR-122 induced metastasis suppression 
We identified and validated two novel target genes of miR-122, RIMS1 and RABL6. A 
significant reduction was observed in luciferase reporter activity of both 3’ UTRs when we 
treated cell lines with the corresponding miRNA-mimics. This was paralleled by a reduction 
in mRNA expression of RIMS1 and RABL6 and in protein expression of RABL6. RIMS1 is a 
member of the RAS gene superfamily and regulates synaptic vesicle exocytosis. It also 
regulates voltage-gated calcium channels during neurotransmitter and insulin release. This 
protein exsits mainly in the brain and is rarely expressed in the colon or liver (Fagerberg et al., 
2014). This is consisitent with our Western blot results for RIMS1 in which we could hardly 
detect this protein. 
RABL6, also known as C9orf86 (chromosome 9 open reading frame 86), or RBEL1 (Rab-like 
protein 1), is a novel subfamily within the Ras superfamily. Montalbano et al. found that 
RABL6 was overexpressed in about 67% of primary breast cancer (Montalbano, Jin, Sheikh, 
& Huang, 2007) , and a knockdown of it RBEL1 resulted in cell growth suppression, which is 
associated with morphological and biochemical features of apoptosis as well as the inhibition 
of extracellular signal-regulated kinase phosphorylation. There are four isoforms of RABL6 
(A, B, C, and D), whereby the larger A and B isoforms are mainly GTP-bound, the smaller C 
and D variants bind to both GTP and GDP  (Montalbano, Lui, Sheikh, & Huang, 2009). 
Furthermore, RABL6A was defined to function as a p53 negative regulator that facilitates 
MDM2-dependent p53 ubiquitylation and degradation (Lui et al., 2013). Some other groups 
also found that RABL6A was an oncogene such as it could promote G1 progression in 
neuroendocrine tumors (NET) by inactivating Rb1, an established suppressor of cancer cell 
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proliferation and development (Hagen et al., 2014). There are no reports up to now 
implicating RABL6 in colorectal cancer. Most of the published reports revolve around breast 
cancer. Consistent with these above published results, in our study, we found that P21 protein 
was upregulated in RABL6 knockdown CRC cells or CRC cells treated by miR-122. This 
suggested that miR-122 induced suppression of RABL6 caused a upregulation of P21, 
although the mechanism by which RABL6 controls P21 is still unknown. P21 is a p53 
transcriptional target and cell cycle inhibitor that blocks cyclin-dependent kinase (Cdk)-
mediated phosphorylation of the retinoblastoma protein (Rb1) (Sherr & McCormick, 2002).  
Furthermore, our data also demonstrated that forced overexpression of miR-122 significantly 
suppressed cell proliferation and colony formation in at least 2 different CRC cell lines. No 
significant difference in cell invasion/migration was however observed, possibly due to the 
function of the main target gene, RABL6.  
Taken together, our findings suggest that miR-122 is an important anti-oncogene in colorectal 
cancer and regulates tumor growth by multiple mechanisms including the silencing of RABL6 
as well as enhancing P21 activation. This activity in the context of liver metastasis implicates 
miR-122 as a potential line of defence against the establishment of liver metastasis and also 
supports a potential use of miR-122 in the therapy of advanced CRC with liver metastasis. 
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6 CONCLUSION 
Metastasis is the leading cause of colorectal cancer (CRC) deaths and the liver is the most 
common metastasis site. Nearly 50% - 60% CRC patients are diagnosed with synchronous 
metastases, 80% of which have liver metastases. Metastasis itself is not a single process but 
rather, a constellation of multiple events that culminate with the colonization of distant sites 
by the primary tumor. 
As preliminary work for the project of this thesis, the whole genomes of 12 patients with 
advanced colorectal cancer were sequenced with the Illumina next generation sequencing 
platform in the Allgayer department. Bioinformatics analysis and subsequent validation 
showed that the miR-122 gene locus was deleted in primary tumors and corresponding 
metastases of most patients. Interestingly, while the expression of miR-122 was suppressed in 
primary tumors, it was significantly increased in metastatic lesions. miR-122 itself is highly 
abundant and specific to the liver and this microRNA plays a critical role in liver homeostasis 
by regulating the expression of a large number of target mRNAs and also by suppressing non-
hepatic genes.  
We found that miR-122 was secreted in the conditioned media and exosomes of Huh7 liver 
cancer cells, which meant that miR-122, could be potentially transferred extracellularly 
through exosomes. Furthermore, in co-culture experiments, we observed an increase of miR-
122 expression in RKO cells from the third day of co-culture with Huh7 cells. This expression 
was still significantly enhanced on the fourth and fifth days. On the other hand, miR-122 
expression was significantly upregulated in RKO and DLD1 cells when we directly added the 
exosomes extracted from conditioned media of Huh7 cells into their normal medium, 
respectively. These two approaches both demonstrated that colorectal cancer cells could take 
up miR-122 secreted from Huh7 cells. This explains our previous paradoxical finding and 
elucidates where the overexpression of miR-122 in the colon cancer cells came from. To date, 
there are no reports about an exosomal interaction involving the delivery of miR-122 to 
colorectal cancer cells in a paracrine fashion.  
We identified and validated two novel target genes of miR-122, RIMS1 and RABL6. RIMS1 
is a member of the RAS gene superfamily and regulates synaptic vesicle exocytosis. It also 
regulates voltage-gated calcium channels during neurotransmitter and insulin release. This 
protein has not been reported yet to be exposed in the colon or liver. RABL6, also known as 
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C9orf86 (chromosome 9 open reading frame 86), or RBEL1 (Rab-like protein 1), is a novel 
subfamily within the Ras superfamily. There are no reports implicating RABL6 in colorectal 
cancer. In our study, we found that P21 protein was upregulated in RABL6 knockdown CRC 
cells, or CRC cells treated with active miR-122. This suggested that the miR-122 induced 
suppression of RABL6 caused a upregulation of P21, although the mechanism by which 
RABL6 controls P21 is still unknown. 
Our data also demonstrated that forced overexpression of miR-122 significantly suppressed 
cell proliferation and colony formation in at least 2 different CRC cell lines. No significant 
difference in cell invasion/migration was however observed, possibly due to the function of 
the main target gene, RABL6.  
In general, our findings suggest that miR-122 is a tumor suppressor in colorectal cancer, and 
regulates tumor growth by multiple mechanisms including the silencing of RABL6 as well as 
enhancing P21 activation. This particular activity in the context of liver metastasis implicates 
miR-122 as a potential line of defence against the establishment of CRC liver metastasis, and 
also supports a potential use of miR-122 in the therapy of advanced CRC with liver metastasis. 
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